Literature DB >> 21304480

Epidemiology of Alzheimer disease.

Christiane Reitz1, Carol Brayne, Richard Mayeux.   

Abstract

The global prevalence of dementia is estimated to be as high as 24 million, and is predicted to double every 20 years through to 2040, leading to a costly burden of disease. Alzheimer disease (AD) is the leading cause of dementia and is characterized by a progressive decline in cognitive function, which typically begins with deterioration in memory. Before death, individuals with this disorder have usually become dependent on caregivers. The neuropathological hallmarks of the AD brain are diffuse and neuritic extracellular amyloid plaques-which are frequently surrounded by dystrophic neurites-and intracellular neurofibrillary tangles. These hallmark pathologies are often accompanied by the presence of reactive microgliosis and the loss of neurons, white matter and synapses. The etiological mechanisms underlying the neuropathological changes in AD remain unclear, but are probably affected by both environmental and genetic factors. Here, we provide an overview of the criteria used in the diagnosis of AD, highlighting how this disease is related to, but distinct from, normal aging. We also summarize current information relating to AD prevalence, incidence and risk factors, and review the biomarkers that may be used for risk assessment and in diagnosis.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21304480      PMCID: PMC3339565          DOI: 10.1038/nrneurol.2011.2

Source DB:  PubMed          Journal:  Nat Rev Neurol        ISSN: 1759-4758            Impact factor:   42.937


  202 in total

1.  CSF phosphorylated tau protein correlates with neocortical neurofibrillary pathology in Alzheimer's disease.

Authors:  Katharina Buerger; Michael Ewers; Tuula Pirttilä; Raymond Zinkowski; Irina Alafuzoff; Stefan J Teipel; John DeBernardis; Daniel Kerkman; Cheryl McCulloch; Hilkka Soininen; Harald Hampel
Journal:  Brain       Date:  2006-09-29       Impact factor: 13.501

Review 2.  Cholesterol paradox: is high total or low HDL cholesterol level a risk for Alzheimer's disease?

Authors:  Makoto Michikawa
Journal:  J Neurosci Res       Date:  2003-04-15       Impact factor: 4.164

3.  Vitamin E and donepezil for the treatment of mild cognitive impairment.

Authors:  Ronald C Petersen; Ronald G Thomas; Michael Grundman; David Bennett; Rachelle Doody; Steven Ferris; Douglas Galasko; Shelia Jin; Jeffrey Kaye; Allan Levey; Eric Pfeiffer; Mary Sano; Christopher H van Dyck; Leon J Thal
Journal:  N Engl J Med       Date:  2005-04-13       Impact factor: 91.245

4.  Midlife vascular risk factors and late-life mild cognitive impairment: A population-based study.

Authors:  M Kivipelto; E L Helkala; T Hänninen; M P Laakso; M Hallikainen; K Alhainen; H Soininen; J Tuomilehto; A Nissinen
Journal:  Neurology       Date:  2001-06-26       Impact factor: 9.910

5.  Apolipoprotein E4 influences amyloid deposition but not cell loss after traumatic brain injury in a mouse model of Alzheimer's disease.

Authors:  Richard E Hartman; Helmut Laurer; Luca Longhi; Kelly R Bales; Steven M Paul; Tracy K McIntosh; David M Holtzman
Journal:  J Neurosci       Date:  2002-12-01       Impact factor: 6.167

6.  A controlled trial of selegiline, alpha-tocopherol, or both as treatment for Alzheimer's disease. The Alzheimer's Disease Cooperative Study.

Authors:  M Sano; C Ernesto; R G Thomas; M R Klauber; K Schafer; M Grundman; P Woodbury; J Growdon; C W Cotman; E Pfeiffer; L S Schneider; L J Thal
Journal:  N Engl J Med       Date:  1997-04-24       Impact factor: 91.245

7.  Leisure-time physical activity at midlife and the risk of dementia and Alzheimer's disease.

Authors:  Suvi Rovio; Ingemar Kåreholt; Eeva-Liisa Helkala; Matti Viitanen; Bengt Winblad; Jaakko Tuomilehto; Hilkka Soininen; Aulikki Nissinen; Miia Kivipelto
Journal:  Lancet Neurol       Date:  2005-11       Impact factor: 44.182

8.  Association of plasma leptin levels with incident Alzheimer disease and MRI measures of brain aging.

Authors:  Wolfgang Lieb; Alexa S Beiser; Ramachandran S Vasan; Zaldy S Tan; Rhoda Au; Tamara B Harris; Ronenn Roubenoff; Sanford Auerbach; Charles DeCarli; Philip A Wolf; Sudha Seshadri
Journal:  JAMA       Date:  2009-12-16       Impact factor: 56.272

9.  Genome-wide association study implicates a chromosome 12 risk locus for late-onset Alzheimer disease.

Authors:  Gary W Beecham; Eden R Martin; Yi-Ju Li; Michael A Slifer; John R Gilbert; Jonathan L Haines; Margaret A Pericak-Vance
Journal:  Am J Hum Genet       Date:  2009-01       Impact factor: 11.025

Review 10.  Leptin and its role in hippocampal synaptic plasticity.

Authors:  Jenni Harvey; Natasha Solovyova; Andrew Irving
Journal:  Prog Lipid Res       Date:  2006-04-21       Impact factor: 16.195

View more
  447 in total

Review 1.  Microglial cell origin and phenotypes in health and disease.

Authors:  Kaoru Saijo; Christopher K Glass
Journal:  Nat Rev Immunol       Date:  2011-10-25       Impact factor: 53.106

Review 2.  New approaches to genetic counseling and testing for Alzheimer's disease and frontotemporal degeneration.

Authors:  Jill S Goldman
Journal:  Curr Neurol Neurosci Rep       Date:  2012-10       Impact factor: 5.081

3.  Inverse effect of the APOE epsilon4 allele in late- and early-onset Alzheimer's disease.

Authors:  Vincenzo De Luca; Maria Donata Orfei; Sara Gaudenzi; Carlo Caltagirone; Gianfranco Spalletta
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2015-12-29       Impact factor: 5.270

Review 4.  The Role of Inflammatory Mediators in the Pathogenesis of Alzheimer's Disease.

Authors:  Gholamreza Azizi; Shadi S Navabi; Ahmed Al-Shukaili; Mir H Seyedzadeh; Reza Yazdani; Abbas Mirshafiey
Journal:  Sultan Qaboos Univ Med J       Date:  2015-08-24

5.  Near-infrared spectroscopy (NIRS) and vagus somatosensory evoked potentials (VSEP) in the early diagnosis of Alzheimer's disease: rationale, design, methods, and first baseline data of the Vogel study.

Authors:  Thomas Polak; Martin J Herrmann; Laura D Müller; Julia B M Zeller; Andrea Katzorke; Matthias Fischer; Fabian Spielmann; Erik Weinmann; Leif Hommers; Martin Lauer; Andreas J Fallgatter; Jürgen Deckert
Journal:  J Neural Transm (Vienna)       Date:  2017-09-01       Impact factor: 3.575

Review 6.  Deep brain stimulation for disorders of memory and cognition.

Authors:  Tejas Sankar; Nir Lipsman; Andres M Lozano
Journal:  Neurotherapeutics       Date:  2014-07       Impact factor: 7.620

Review 7.  The nature, significance, and glucagon-like peptide-1 analog treatment of brain insulin resistance in Alzheimer's disease.

Authors:  Konrad Talbot; Hoau-Yan Wang
Journal:  Alzheimers Dement       Date:  2014-02       Impact factor: 21.566

8.  Functional connectivity and graph theory in preclinical Alzheimer's disease.

Authors:  Matthew R Brier; Jewell B Thomas; Anne M Fagan; Jason Hassenstab; David M Holtzman; Tammie L Benzinger; John C Morris; Beau M Ances
Journal:  Neurobiol Aging       Date:  2013-10-18       Impact factor: 4.673

9.  Periodontal disease associates with higher brain amyloid load in normal elderly.

Authors:  Angela R Kamer; Elizabeth Pirraglia; Wai Tsui; Henry Rusinek; Shankar Vallabhajosula; Lisa Mosconi; Li Yi; Pauline McHugh; Ronald G Craig; Spencer Svetcov; Ross Linker; Chen Shi; Lidia Glodzik; Schantel Williams; Patricia Corby; Deepak Saxena; Mony J de Leon
Journal:  Neurobiol Aging       Date:  2014-11-05       Impact factor: 4.673

10.  Identification of CHCHD10 Mutation in Chinese Patients with Alzheimer Disease.

Authors:  Tingting Xiao; Bin Jiao; Weiwei Zhang; Chuzheng Pan; Jingya Wei; Xiaoyan Liu; Yafang Zhou; Lin Zhou; Beisha Tang; Lu Shen
Journal:  Mol Neurobiol       Date:  2016-08-30       Impact factor: 5.590

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.